Dr Reddy’s Laboratories Ltd announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox (moxifloxacin HCl) tablets 400mg in the US market on Tuesday.
The product has been approved from the US Food and Drug Administration, a release from the Hyderabad-based pharma major said.
The Avelox tablets brand had US sales of approximately $195 million for the most recent 12 months ended in December 2013 according to IMS Health.
Dr Reddy’s Moxifloxacin Hydrochloride Tablets, 400 mg is available in bottle counts of 30.